nRichDX Welcomes Dr. Daniel Kim to Scientific Advisory Board to Enhance Liquid Biopsy Development

nRichDX Enhances Scientific Advisory Board with the Addition of Dr. Daniel Kim

In a pivotal move to strengthen its scientific prowess, nRichDX has announced the appointment of Dr. Daniel Kim, a renowned expert in RNA liquid biopsy technology, to its Scientific Advisory Board. Dr. Kim joins nRichDX at a critical time as it prepares to launch its fully automated Revolution Pro™ instrument at the upcoming Association of Molecular Pathology (AMP) meeting scheduled for November 11-14 in Seattle, WA. This appointment promises to enhance nRichDX's capabilities in liquid biopsy sample extraction and analysis, crucial for advancing early cancer detection and research.

Dr. Daniel Kim holds a prestigious position as an Assistant Professor at the University of California, Santa Cruz, and is an Associate Member at the Canary Center at Stanford University for Cancer Early Detection. His extensive expertise encompasses RNA profiling and the development of molecular biomarkers that facilitate the early detection of various diseases, particularly cancer. Recognized as a leading voice in the field, he has served as Co-Chair of the NIH Liquid Biopsy Scientific Interest Group and the International Society for Extracellular Vesicles (ISEV) RNA Task Force.

Strengthening Scientific Expertise

With Dr. Kim’s appointment, nRichDX aims to bolster its scientific advisory capabilities, optimizing sample preparation solutions that support research on cell-free RNA (cfRNA), cell-free DNA (cfDNA), and circulating cell-free total nucleic acids (cfTNA). His research is particularly focused on integrating transcriptomics, analyzing extracellular vesicles, and employing AI-driven informatics. Furthermore, Dr. Kim has an interest in leveraging long-read nanopore sequencing to explore disease biology and therapeutic advancements.

nRichDX CEO William Curtis emphasized the talent that Dr. Kim brings to the team, stating, "Daniel brings an exceptional understanding of RNA biology and the technologies needed to translate circulating cell-free molecular signals into meaningful scientific insights. His perspective will help guide our efforts to address the sample preparation needs of assay developers advancing non-invasive liquid biopsy solutions, particularly in early cancer detection."

Upcoming Launch of Revolution Pro™

The timing of Dr. Kim’s appointment aligns perfectly with nRichDX's imminent launch of the Revolution Pro™ device, designed to facilitate large-scale research and development projects in translational medicine. As the demand for life-saving liquid biopsy tests grows, nRichDX is prepared to lead the way in enhancing diagnostic methodologies that could change patient care pathways.

Dr. Kim expressed enthusiasm about joining nRichDX, stating, "Circulating cell-free RNA offers a rich view into disease biology, with exciting possibilities for early detection in the clinic, as well as biomarker discovery, therapeutic research, and translational medicine. I look forward to working with nRichDX at this exciting time to help advance solutions that support the evolving needs of the broader liquid biopsy community."

The Importance of Liquid Biopsies

Liquid biopsies represent a revolutionary approach to understanding the dynamic molecular changes associated with diseases. These procedures make it possible to detect and analyze cellular materials present in bodily fluids, offering insights that are not only valuable for cancer but also for various medical conditions. Successful sample preparation and signal extraction are crucial for ensuring a high yield of target signals that facilitate optimal and consistent diagnostic outcomes.

As a new member of nRichDX’s Scientific Advisory Board, Dr. Kim will play a vital role in providing guidance on emerging RNA research, ensuring the company's methodologies remain at the forefront of next-generation molecular profiling technologies. With innovations in RNA-based liquid biopsy approaches, nRichDX is poised to make significant contributions to early disease detection and therapy.

For more detailed information about nRichDX and its revolutionary technologies, please visit nrichdx.com and follow the company on LinkedIn.